Affinage

MBL2

Mannose-binding protein C · UniProt P11226

Length
248 aa
Mass
26.1 kDa
Annotated
2026-06-10
100 papers in source corpus 17 papers cited in narrative 17 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MBL2 encodes mannose-binding lectin (MBL), a calcium-dependent C-type lectin collectin that recognizes oligosaccharide arrays on microbial surfaces and initiates the lectin pathway of complement activation (PMID:9777416). Each polypeptide pairs a collagen-like domain with a C-type lectin domain; polypeptides trimerize and assemble into higher-order oligomers (typically 12–18 chains), and MBL is the only collectin able to activate complement (PMID:12887296). Surface binding triggers associated MBL-associated serine proteases: MASP-2 is the principal complement-activating protease, cleaving C4 and C2 to generate the C3 convertase (C4b2a), while MASP-1/3 contribute additionally to C3 deposition (PMID:12396008, PMID:17892207). Functional studies of human sera and the MBL complex indicate that MBL circulates as distinct MBL–MASP-1 and MBL–MASP-2 subpopulations rather than a fixed stoichiometric complex, and that complex assembly and activity are regulated by C1-inhibitor and by the MASP1-derived splice product MAP-1, which forms inhibitory heterocomplexes with MASP-1 and MASP-3 (PMID:11257302, PMID:16102832, PMID:24683193). Common exon-1 mutations at codons 52, 54, or 57 disrupt the collagen-like triple helix and prevent assembly of functional higher-order oligomers, producing low-molecular-mass circulating MBL with impaired mannan binding and complement-activating activity rather than complete protein absence (PMID:12887296, PMID:14515259). Beyond complement, MBL binds endothelial cells through its collagenous domain in competition with C1q (PMID:16911830), and modulates monocyte cytokine responses by suppressing LPS-induced IL-1 and enhancing IL-10, IL-1Ra, and IL-6 (PMID:16617157). MBL recognizes pathogen glycans including HIV-1 gp120 high-mannose glycans, opsonizing the virus and blocking DC-SIGN interaction (PMID:15488604), though its role in infection is context-dependent, with both protective and deleterious outcomes observed in animal models (PMID:17892207, PMID:20064561).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1998 High

    Established that MBL is a pattern-recognition molecule whose surface binding triggers a protease cascade, defining the lectin pathway of complement as a distinct innate immune activation route.

    Evidence In vitro functional assays of MBL-MASP complex activity on microbial oligosaccharides

    PMID:9777416

    Open questions at the time
    • Did not resolve which MASP is the primary activating protease
    • Stoichiometry of MBL-MASP complexes not defined
  2. 2002 High

    Resolved the division of labor among MASPs, showing MASP-2 is the C4/C2-cleaving convertase-forming enzyme while MASP-1 has slow C3 and extra-complement (fibrinogen, FXIII) activities.

    Evidence In vitro enzymatic assays with purified recombinant and native MASP-1 and MASP-2

    PMID:12396008

    Open questions at the time
    • Physiological significance of MASP-1 C3 cleavage unresolved
    • Quantitative contribution of MASP-1 to lectin pathway in vivo not addressed
  3. 2003 High

    Connected genotype to molecular phenotype, demonstrating that exon-1 codon 52/54/57 mutations disrupt the collagen-like triple helix, preventing functional oligomer assembly and explaining MBL deficiency.

    Evidence Biochemical/structural characterization and serum MBL quantitation across known MBL2 genotypes

    PMID:12887296 PMID:14515259

    Open questions at the time
    • Quantitative threshold of oligomer size needed for complement activation not defined
    • How residual low-mass MBL behaves in tissue not addressed
  4. 2003 Medium

    Confirmed that recombinant MBL faithfully reproduces native oligomeric assembly, modifications, and complement-activating function, enabling reagent-grade study and therapeutic production.

    Evidence Recombinant expression in human cell line with functional assay and mass spectrometry comparison to plasma MBL

    PMID:12887299

    Open questions at the time
    • Single-lab MS comparison
    • Long-term stability and in vivo behavior of recombinant MBL not assessed
  5. 2005 Medium

    Provided serum-level evidence that MBL-MASP-1 and MBL-MASP-2 exist as separate complex populations rather than a fixed ternary complex, reframing how lectin pathway activity is apportioned.

    Evidence ELISA and activity assays (amidolytic for MASP-1, C4 fixation for MASP-2) across 152 sera

    PMID:16102832

    Open questions at the time
    • Correlative population data, not direct structural separation of complexes
    • Determinants of complex preference unknown
  6. 2005 Medium

    Demonstrated MBL recognition of HIV-1 gp120 high-mannose glycans, defining an antiviral opsonic and DC-SIGN-blocking role and linking glycan processing to neutralization potency.

    Evidence Binding, complement activation, neutralization, and DC-SIGN competition assays on gp120

    PMID:15488604

    Open questions at the time
    • Weak neutralization of primary isolates
    • In vivo antiviral relevance not established
  7. 2006 Medium

    Extended MBL function beyond complement by showing it reprograms monocyte cytokine output, dampening proinflammatory IL-1 while boosting anti-inflammatory and chemotactic mediators.

    Evidence Treatment of human PBMCs under phagocytosis-enhancing conditions with cytokine mRNA and protein readouts

    PMID:16617157

    Open questions at the time
    • Receptor mediating cytokine modulation not identified
    • Single-lab primary cell study
  8. 2006 Medium

    Identified a complement-independent endothelial interaction in which MBL binds via its collagenous domain and competes with C1q for a shared receptor, suggesting non-canonical surface roles.

    Evidence Flow cytometry binding and cross-competition assays on HUVEC with labeled MBL and C1q

    PMID:16911830

    Open questions at the time
    • Shared receptor molecular identity unknown
    • Functional consequence of endothelial binding not defined
  9. 2006 Medium

    Clarified the structural basis of recognition-protein/protease assembly, showing MASPs and C1r/C1s use a common CUB1-EGF region but distinct dimer strategies to engage MBL versus C1q.

    Evidence Structural and 3D functional studies summarized across primary work

    PMID:17544813

    Open questions at the time
    • Review-level synthesis rather than single primary structure
    • Atomic detail of MBL-MASP contact not fully resolved here
  10. 2007 High

    Genetically dissected MASP contributions in vivo, confirming MASP-2 as the primary activator while showing MASP-1/3 promote C3 deposition and antiviral defense.

    Evidence MASP-deficient knockout mice with C3 deposition assays and influenza challenge

    PMID:17892207

    Open questions at the time
    • Mechanism of MASP-1/3 contribution to C3 deposition not fully resolved
    • Mouse-to-human extrapolation
  11. 2010 Medium

    Revealed regulatory architecture of the lectin pathway by characterizing MAP-1, a MASP1 splice product that circulates with recognition molecules and forms calcium-dependent inhibitory heterocomplexes with MASP-1 and MASP-3.

    Evidence Recombinant expression, ELISA, ultracentrifugation, SEC, immunoblot in serum/plasma and recognition-molecule-depleted serum

    PMID:21035894 PMID:24683193

    Open questions at the time
    • Quantitative inhibitory potency of MAP-1 in vivo not established
    • Single-lab characterization
  12. 2010 Medium

    Challenged a purely protective view of MBL by showing it can be deleterious, with MBL-knockout mice no more (and sometimes less) susceptible to systemic aspergillosis.

    Evidence MBL-A/MBL-C double knockout mice with dose-response Aspergillus challenge and survival monitoring

    PMID:20064561

    Open questions at the time
    • Mechanism of the deleterious effect not defined
    • Pathogen- and route-specific generalizability unclear
  13. 2022 High

    Demonstrated active pathogen evasion of MBL-mediated complement, with Fasciola hepatica both escaping MBL surface binding and secreting serpins that inhibit MASPs to block C3b/C4b deposition.

    Evidence Purified MBL binding assays, recombinant serpin MASP-inhibition assays, immunofluorescence, and deposition assays in human serum

    PMID:35007288

    Open questions at the time
    • Whether these mechanisms operate across other parasites unknown
    • Structural basis of serpin-MASP inhibition not defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • The receptor(s) mediating MBL's complement-independent endothelial binding and monocyte cytokine modulation remain molecularly unidentified, and the in vivo determinants partitioning MBL into distinct MASP subcomplexes are unresolved.
  • Shared MBL/C1q endothelial receptor not cloned
  • Signaling pathway for cytokine modulation undefined
  • Regulation of MBL-MASP-1 vs MBL-MASP-2 complex formation unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Localization
GO:0005576 extracellular region 3
Pathway
R-HSA-168256 Immune System 3
Partners
C1QAC2C4MAP-1MASP1MASP2
Complex memberships
MBL-MASP lectin pathway complex

Evidence

Reading pass · 17 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 MBL2-encoded mannose-binding lectin (MBL) binds to oligosaccharides on microbial surfaces in a calcium-dependent manner through multiple C-type lectin domains, and upon surface binding activates a pro-serine protease complex (MASP-1 and MASP-2) leading to cleavage of complement components C4 and C2, initiating the lectin pathway of complement activation. In vitro functional assays, biochemical characterization of MBL-MASP complexes Immunobiology High 9777416
2002 MASP-2, when complexed with MBL, cleaves complement C4 and C2 to form C3 convertase (C4b2a), directly activating the complement cascade. MASP-1 can cleave C3 directly but this activity is very slow and may not be biologically significant; additionally, MASP-1 cleaves fibrinogen (releasing fibrinopeptide B) and activates plasma transglutaminase (Factor XIII). In vitro enzymatic assays with purified recombinant and native MASP-1 and MASP-2 proteins Immunobiology High 12396008
2000 The MBL complex (comprising MBL, MASP-1, MASP-2, and MAp19) is inhibited by C1-inhibitor, which associates with the complex. Alpha-2-macroglobulin (alpha2M) was found to associate with the MBL complex but did not inhibit complement activation via this pathway. At physiological ionic strength, MASP-1, MASP-2, MAp19, and associated inhibitors dissociate from MBL, whereas high ionic strength (1 M NaCl) stabilizes the complex. Complement activation assay specific for the MBL pathway; protein association studies with MBL complex from serum Molecular immunology Medium 11257302
2003 MBL is a collectin assembled from polypeptide subunits each containing a collagen-like domain followed by a C-type lectin domain; polypeptides trimerize to form subunits that associate into higher-order oligomers (typically 12-18 polypeptides). Mutations in the collagen-like region (at codons 52, 54, or 57 in exon 1) disrupt triple helix formation, preventing assembly of functional higher-order oligomers and reducing serum MBL. MBL is the only collectin that activates complement, doing so through MASP-2 which activates C4 and C2, analogously to the C1q pathway. Biochemical characterization, structural analysis, serum MBL quantitation with known genotypes Biochemical Society transactions High 12887296
2003 MBL forms two molecular forms in serum: a high-molecular-mass form and a lower-molecular-mass form. The high-molecular form (present in wild-type A/A homozygotes) binds mannan and associates with MASP-1/3, while the low-molecular form (present in homozygous codon-54 mutants, B/B) lacks these functional capabilities. Thus, MBL deficiency-associated mutations produce circulating oligomeric MBL with impaired functional activity rather than complete absence of protein. Gel filtration of sera from individuals of known MBL2 genotype; ELISA for MBL; functional binding assays to mannan and MASP-1/3 European journal of immunology Medium 14515259
2005 MBL binds to HIV-1 via high-mannose glycans on gp120; this binding activates complement on gp120 and opsonizes HIV. MBL was shown to block the interaction between HIV and DC-SIGN. Direct neutralization of HIV produced in T cell lines was observed, though neutralization of primary isolates was low; drugs altering carbohydrate processing enhanced neutralization of primary isolates by MBL. Binding assays, complement activation assays on gp120, neutralization assays, DC-SIGN competition assays Molecular immunology Medium 15488604
2005 Human MBL2 gene is transcribed from two alternative promoters (promoter 0 and promoter 1); promoter 0 produces transcripts with an additional 5' untranslated exon (exon 0). Low-level extra-hepatic mbl2 mRNA expression occurs predominantly in small intestine and testis tissue, dominated by promoter 1 transcripts. Alternative acceptor splice sites within exon 1 generate additional transcript variants. RT-PCR, quantitative PCR, RNA analysis from multiple human tissues; promoter-specific analysis Molecular immunology Medium 16112196
2006 MBL, under conditions enhancing phagocytosis, modulates cytokine production in human peripheral blood mononuclear cells: it suppresses LPS-induced proinflammatory cytokines IL-1alpha and IL-1beta, and increases secretion of IL-10, IL-1 receptor antagonist, monocyte chemoattractant protein-1, and IL-6, at both mRNA and protein levels. Treatment of human PBMCs with MBL under phagocytosis-enhancing conditions; measurement of cytokine mRNA and protein Journal of leukocyte biology Medium 16617157
2006 MBL binds to human umbilical vein endothelial cells (HUVEC) in a dose-dependent, calcium-independent manner involving its collagenous domains. MBL and C1q compete for binding to a shared receptor on endothelial cells; pre-incubation with MBL inhibits subsequent C1q binding and vice versa. LPS activation of HUVEC increases both C1q and MBL binding. MBL stimulation of HUVEC did not detectably increase cytokine production. Flow cytometry binding assays on HUVEC; cross-competition experiments with digoxygenin-labeled MBL and C1q Molecular immunology Medium 16911830
2006 The MBL-MASP and C1 complexes share a common assembly mechanism: C1r/C1s and MASPs associate with their partner recognition proteins (C1q and MBL/ficolins, respectively) through a common mechanism involving their N-terminal CUB1-EGF region; however, the C1s-C1r-C1r-C1s tetramer and the (MASP)2 dimers use distinct strategies to associate with their partner proteins. Structural and functional studies, 3D structural investigations Immunobiology Medium 17544813
2007 MASP-2 is the primary complement-activating protease in the MBL complex, cleaving C4 and C2 to form C3 convertase. In MASP-1/MASP-3-deficient mice, C3 deposition on mannan and zymosan surfaces was reduced, indicating MASP-1/3 also contribute to lectin pathway complement activation. MASP-1/3-deficient mice showed increased susceptibility to influenza virus. MASP-deficient knockout mouse models; C3 deposition assay on mannan/zymosan surfaces; viral infection challenge Advances in experimental medicine and biology High 17892207
2005 In a population of 152 healthy individuals, MASP-1 and MASP-2 activities were each correlated with MBL concentration. However, when normalized to MBL concentration, MASP-1 activity was inversely correlated with MASP-2 activity. This finding is consistent with separate, distinct populations of MBL-MASP-1 complexes and MBL-MASP-2 complexes in serum, without fixed MBL-(MASP-1)-(MASP-2) stoichiometry. ELISA for MBL; amidolytic assay for MASP-1 activity; C4 fixation assay for MASP-2 activity on mannan-bound MBL from 152 sera Molecular immunology Medium 16102832
2010 MAP-1 (MBL/ficolin associated protein-1, derived from the MASP1 gene via differential splicing) circulates in serum primarily in complex with Ficolin-3, and to a lesser degree with Ficolin-2 and MBL. MAP-1 is a glycosylated serum protein (~45 kDa, reduced to ~40 kDa after N-glycosidase F treatment). Recombinant MAP-1 expression; quantitative ELISA; density gradient ultracentrifugation; N-glycosidase F treatment Immunobiology Medium 21035894
2014 MAP-1 forms heterocomplexes with MASP-1 and MASP-3 in a calcium-dependent manner, as detected in both recombinant protein experiments and native human serum/plasma. MASP-1 and MASP-3 also form heterocomplexes with each other. Free circulating MAP-1/MASP heterocomplexes exist in blood independently of lectin pathway recognition molecules. ELISA, size-exclusion chromatography, immunoblotting using recombinant proteins and serum/plasma; depletion of recognition molecules from ficolin-3-deficient serum Journal of immunology Medium 24683193
2022 The helminth parasite Fasciola hepatica evades MBL-mediated complement killing through two mechanisms: (1) MBL does not bind to the surface of live newly excysted juveniles (NEJ) despite mannosylated surface proteins; (2) recombinant serine protease inhibitors secreted by NEJ (rFhSrp1 and rFhSrp2) selectively inhibit native and recombinant MASPs, preventing C3b and C4b deposition on NEJ. Immunofluorescence confirmed absence of MBL, C3b, C4b, and MAC on NEJ surface incubated in normal human serum. Binding assays with purified MBL; recombinant serpin inhibition assays with native and recombinant MASPs; immunofluorescence microscopy; C3b/C4b deposition assays PLoS pathogens High 35007288
2010 In MBL gene-knockout mice (lacking both MBL-A and MBL-C), susceptibility to experimental systemic aspergillosis was not greater than wild-type mice; at lower inocula, MBL-KO mice were actually less susceptible to lethal infection, suggesting MBL may play a deleterious (rather than protective) role in systemic aspergillosis. MBL-A and MBL-C double knockout mouse model; intravenous challenge with Aspergillus fumigatus conidia at multiple doses; survival monitoring Immunology letters Medium 20064561
2003 Recombinant MBL produced in a transfected human cell line shows the same biological activity (complement activation and opsonization) and essentially identical mass spectrometry profile as plasma-derived MBL, confirming that oligomeric assembly and post-translational modifications are preserved in recombinant production. Recombinant expression in human cell line; functional complement activation assay; mass spectrometry comparison to plasma-derived MBL Biochemical Society transactions Medium 12887299

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1993 A role for the transcription factors Mbp1 and Swi4 in progression from G1 to S phase. Science (New York, N.Y.) 341 8372350
2016 A journey through the lectin pathway of complement-MBL and beyond. Immunological reviews 333 27782323
2002 MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet (London, England) 237 12047967
2010 Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 171 20090778
1998 Mannose-binding lectin (MBL) in health and disease. Immunobiology 140 9777416
2006 C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. Journal of leukocyte biology 126 16617157
2009 MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Molecular immunology 122 19501910
2002 The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 118 12396008
2000 Control of the classical and the MBL pathway of complement activation. Molecular immunology 109 11257302
2005 Mannose binding lectin (MBL) and HIV. Molecular immunology 105 15488604
1997 Xbp1, a stress-induced transcriptional repressor of the Saccharomyces cerevisiae Swi4/Mbp1 family. Molecular and cellular biology 92 9343412
2005 Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. Journal of clinical immunology 90 16380821
2005 Extra-hepatic transcription of the human mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 genes. Molecular immunology 85 16112196
2010 Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry. Part B, Clinical cytometry 83 20839333
2013 Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood 69 23596047
2003 Recombinant mannan-binding lectin (MBL) for therapy. Biochemical Society transactions 62 12887299
2008 The activated Notch1 receptor cooperates with alpha-enolase and MBP-1 in modulating c-myc activity. Molecular and cellular biology 58 18490439
2008 C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. Trends in molecular medicine 57 18977695
2003 Relationship between gene polymorphisms of mannose-binding lectin (MBL) and two molecular forms of MBL. European journal of immunology 55 14515259
2015 MBL-associated serine proteases (MASPs) and infectious diseases. Molecular immunology 51 25862418
2012 MBL2, MASP2, AMELX, and ENAM gene polymorphisms and dental caries in Polish children. Oral diseases 50 22221294
1999 Association of the cell cycle transcription factor Mbp1 with the Skn7 response regulator in budding yeast. Molecular biology of the cell 49 10512874
1999 MBP1: a novel mutant p53-specific protein partner with oncogenic properties. Oncogene 48 10380882
2014 Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours. Cancer immunology, immunotherapy : CII 45 25038892
2013 Downregulation of tumor suppressor MBP-1 by microRNA-363 in gastric carcinogenesis. Carcinogenesis 44 23975832
2021 The ambiguous role of mannose-binding lectin (MBL) in human immunity. Open medicine (Warsaw, Poland) 43 33681468
2008 MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue phenotype. Human immunology 43 18361938
2009 MBP-1 suppresses growth and metastasis of gastric cancer cells through COX-2. Molecular biology of the cell 41 19846662
2003 Biochemistry and genetics of mannan-binding lectin (MBL). Biochemical Society transactions 41 12887296
2000 Characterization of the DNA-binding domains from the yeast cell-cycle transcription factors Mbp1 and Swi4. Biochemistry 41 10747782
2007 Role of MBL-associated serine protease (MASP) on activation of the lectin complement pathway. Advances in experimental medicine and biology 40 17892207
1997 Crystal structure of the DNA-binding domain of Mbp1, a transcription factor important in cell-cycle control of DNA synthesis. Structure (London, England : 1993) 40 9083114
2005 c-myc Promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway. The Journal of biological chemistry 39 15805119
1998 MASP1 (MBL-associated serine protease 1). Immunobiology 38 9777417
2022 Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. Blood 35 36206503
2007 Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. Journal of the National Cancer Institute 35 17848669
2005 Mannose-binding lectin 2 (MBL2) gene polymorphism in asthma and atopy among adults. Clinical and experimental immunology 35 16178865
2011 A flucytosine-responsive Mbp1/Swi4-like protein, Mbs1, plays pleiotropic roles in antifungal drug resistance, stress response, and virulence of Cryptococcus neoformans. Eukaryotic cell 34 22080454
2021 Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. Molecular and cellular biochemistry 33 33745077
2021 Transcription Activator Swi6 Interacts with Mbp1 in MluI Cell Cycle Box-Binding Complex and Regulates Hyphal Differentiation and Virulence in Beauveria bassiana. Journal of fungi (Basel, Switzerland) 33 34070348
2000 Mannan-binding lectin (MBL) in chickens: molecular and functional aspects. Developmental and comparative immunology 33 10717281
2019 Mbp1, a component of the MluI cell cycle box-binding complex, contributes to morphological transition and virulence in the filamentous entomopathogenic fungus Beauveria bassiana. Environmental microbiology 31 31743555
2017 Characterization of BRPMBL, the Bleomycin Resistance Protein Associated with the Carbapenemase NDM. Antimicrobial agents and chemotherapy 31 28069656
2015 Impact of MBL and MASP-2 gene polymorphism and its interaction on susceptibility to tuberculosis. BMC infectious diseases 31 25887173
2014 Restoration of MBL-deficiency: redefining the safety, efficacy and viability of MBL-substitution therapy. Molecular immunology 31 25044097
2009 Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy. Diabetes 31 19366862
2008 Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients. Journal of clinical immunology 29 18592362
2013 MBL2 variations and malaria susceptibility in Indian populations. Infection and immunity 28 24126531
2022 Progression and survival of MBL: a screening study of 10 139 individuals. Blood 27 35969843
2005 Mannose-binding lectin (MBL) and vascular complications in diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 27 15918118
2013 MBL2 gene polymorphisms and susceptibility to tuberculosis in a northeastern Brazilian population. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 26 23524205
2008 MBL2 and MASP2 gene polymorphisms in patients with hepatocellular carcinoma. Journal of viral hepatitis 26 18221301
2006 Tumor-suppressive effects of MBP-1 in non-small cell lung cancer cells. Cancer research 26 17178888
2012 The relationship between the variants of the bovine MBL2 gene and milk production traits, mastitis, serum MBL-C levels and complement activity. Veterinary immunology and immunopathology 24 22771198
2011 Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) genotypes in colorectal cancer. Scandinavian journal of immunology 23 21198752
2006 MBL and C1q compete for interaction with human endothelial cells. Molecular immunology 23 16911830
2006 Assembly of C1 and the MBL- and ficolin-MASP complexes: structural insights. Immunobiology 23 17544813
2005 Heterogeneity of MBL-MASP complexes. Molecular immunology 23 16102832
2022 Fasciola hepatica is refractory to complement killing by preventing attachment of mannose binding lectin (MBL) and inhibiting MBL-associated serine proteases (MASPs) with serpins. PLoS pathogens 22 35007288
2016 A Meta-analysis of MBL2 Polymorphisms and Tuberculosis Risk. Scientific reports 21 27876780
2016 Association of MBL2 Gene Polymorphism with Dental Caries in Saudi Children. Caries research 21 27894112
2010 SEDLIN forms homodimers: characterisation of SEDLIN mutations and their interactions with transcription factors MBP1, PITX1 and SF1. PloS one 21 20498720
2010 Serum concentration and interaction properties of MBL/ficolin associated protein-1. Immunobiology 21 21035894
2016 Genetically Determined MBL Deficiency Is Associated with Protection against Chronic Cardiomyopathy in Chagas Disease. PLoS neglected tropical diseases 20 26745156
2010 Resistance of MBL gene-knockout mice to experimental systemic aspergillosis. Immunology letters 20 20064561
2018 The Biological Significance and Regulatory Mechanism of c-Myc Binding Protein 1 (MBP-1). International journal of molecular sciences 19 30518090
2002 MBP-1 mediated apoptosis involves cytochrome c release from mitochondria. Oncogene 19 11973636
2012 Mutations of complement lectin pathway genes MBL2 and MASP2 associated with placental malaria. Malaria journal 18 22380611
2008 Association between MBL2 gene functional polymorphisms and high-risk human papillomavirus infection in Brazilian women. Human immunology 18 18486762
2001 Structure and function of complement activating enzyme complexes: C1 and MBL-MASPs. Current protein & peptide science 18 12369900
1998 Failure of central nervous system myelination in MBP/c-myc transgenic mice: evidence for c-myc cytotoxicity. Oncogene 18 9572493
2024 Genomic instability and genetic heterogeneity in aging: insights from clonal hematopoiesis (CHIP), monoclonal gammopathy (MGUS), and monoclonal B-cell lymphocytosis (MBL). GeroScience 17 39405013
2023 Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups. Frontiers in immunology 17 37051252
2014 Heterocomplex formation between MBL/ficolin/CL-11-associated serine protease-1 and -3 and MBL/ficolin/CL-11-associated protein-1. Journal of immunology (Baltimore, Md. : 1950) 17 24683193
2013 Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer. BMC cancer 17 23421821
2013 Chicken mannose-binding lectin (MBL) gene variants with influence on MBL serum concentrations. Immunogenetics 17 23455474
2020 Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients diagnosed with schizophrenia or bipolar disorder. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 16 32279906
2019 Association between the mannose-binding lectin (MBL)-2 gene variants and serum MBL with pulmonary tuberculosis: An update meta-analysis and systematic review. Microbial pathogenesis 16 30999018
2012 Genetic variants of the MBL2 gene are associated with mortality in pneumococcal sepsis. Diagnostic microbiology and infectious disease 16 22578937
2012 Association of MIF-173G/C and MBL2 codon 54 gene polymorphisms with rheumatoid arthritis: a meta-analysis. Human immunology 16 22820623
2010 Mannose binding lectin (MBL) in autoimmunity and its role in systemic lupus erythematosus (SLE). The Journal of the Association of Physicians of India 16 21510462
2009 Genetic and structural analysis of MBL2 and MASP2 polymorphisms in south-eastern African children. Tissue antigens 16 19775369
2000 The influence of DNA binding on the backbone dynamics of the yeast cell-cycle protein Mbp1. Journal of biomolecular NMR 16 10805125
2023 Polymorphisms in the MBL2 gene are associated with the plasma levels of MBL and the cytokines IL-6 and TNF-α in severe COVID-19. Frontiers in immunology 15 37138871
2020 Complement protein levels and MBL2 polymorphisms are associated with dengue and disease severity. Scientific reports 15 32913345
2018 Correlation between MBL2/CD14/TNF-α gene polymorphisms and susceptibility to spinal tuberculosis in Chinese population. Bioscience reports 15 29298876
2013 Replication study in Chinese Han population and meta-analysis supports association between the MBL2 gene polymorphism and HIV-1 infection. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 15 24035792
2012 Association between bronchopulmonary dysplasia and MBL2 and IL1-RN polymorphisms. Pediatrics international : official journal of the Japan Pediatric Society 15 22882323
2011 Mannan-binding lectin (MBL) and MBL-associated serine protease-2 in children with cancer. Swiss medical weekly 15 21528466
2012 MBL2 gene variation affecting serum MBL is associated with prosthetic joint infection in Czech patients after total joint arthroplasty. Tissue antigens 14 22994203
2009 MBP-1 inhibits breast cancer growth and metastasis in immunocompetent mice. Cancer research 14 19934312
2003 NMR structure of the DNA-binding domain of the cell cycle protein Mbp1 from Saccharomyces cerevisiae. Biochemistry 14 12564929
2022 Age- and Sex-Matched Normal Leukocyte Subset Ranges in the General Population Defined with the EuroFlow Lymphocyte Screening Tube (LST) for Monoclonal B-Cell Lymphocytosis (MBL) vs. Non-MBL Subjects. Cancers 13 36612056
2018 MBL2 gene polymorphism rs1800450 and rheumatic fever with and without rheumatic heart disease: an Egyptian pilot study. Pediatric rheumatology online journal 13 29653582
2015 MBL2 genotypes and their associations with MBL levels and NICU morbidity in a cohort of Greek neonates. Journal of immunology research 13 25879044
2012 Association of RANTES and MBL gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Molecular biology reports 13 23065234
2024 Putative APSES family transcription factor mbp1 plays an essential role in regulating cell wall synthesis in the agaricomycete Pleurotus ostreatus. Fungal genetics and biology : FG & B 12 39369812
2022 A novel Bacteroides metallo-β-lactamase (MBL) and its gene (crxA) in Bacteroides xylanisolvens revealed by genomic sequencing and functional analysis. The Journal of antimicrobial chemotherapy 12 35296904
2016 Association of MBL2 exon1 polymorphisms with high-risk human papillomavirus infection and cervical cancers: a meta-analysis. Archives of gynecology and obstetrics 12 27619685
1997 Separate domains of MBP-1 involved in c-myc promoter binding and growth suppressive activity. Gene 12 9074493

Missed literature

Know a paper Affinage missed for MBL2? Flag it for the maintainers and the community.

No submissions yet.